Hepion Pharmaceuticals Competitors and Similar CompaniesClear all

Hepion Pharmaceuticals's competitors and similar companies include Novartis, Moderna, Regeneron Pharmaceuticals and Ajinomoto Bio-Pharma Services.

	Hepion Pharmaceuticals Hepion Pharmaceuticals (formerly known as ContraVir Pharmaceuticals) is a clinical-stage biopharmaceutical company focused on the development of targeted therapies for liver disease.	Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products.	Moderna Moderna (formerly Moderna Therapeutics) is a biotechnology company focused on messenger RNA (mRNA) medicine.	Regeneron Pharmaceuticals Regeneron Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets medicines.	Ajinomoto Bio-Pharma Services Ajinomoto Bio-Pharma Services (formerly known as Ajinomoto Althea) is a contract development and manufacturing organization (CDMO).
Founding Date	Founding Date 2013	Founding Date 1996	Founding Date 2010	Founding Date 1988	Founding Date 1998
Type	Type Public	Type Public	Type Public	Type Public	Type Subsidiary
Tags	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development oncology pharma	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development pharma
Locations	Locations Edison, US HQ Edmonton, CA	Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more	Locations Cambridge, US HQ Melbourne, AU Paris, FR München, DE Tokyo, JP Seoul, KR Warszawa, PL see more	Locations Tarrytown, US HQ Mississauga, CA Courbevoie, FR München, DE Bengaluru, IN Dublin, IE Limerick, IE see more	Locations San Diego, US HQ Wetteren, BE Visakhapatnam, IN Osaka, JP
Employees	Employees 1430% decrease	Employees 75,883	Employees 5,8004% increase	Employees 15,1068% increase	Employees 68610% decrease
Valuation ($)	Valuation ($) 3.8 m	Valuation ($) N/A	Valuation ($) 21.2 b	Valuation ($) 102.2 b	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $56.7b (FY, 2025)	Revenue (est.) $1.9b (FY, 2025)	Revenue (est.) $14.3b (FY, 2025)	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods $8.4b (FY, 2025)	Cost of goods $868m (FY, 2025)	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit $49.8b (FY, 2025)	Gross profit $1.1b (FY, 2025)	Gross profit N/A	Gross profit N/A
Net income	Net income ($8.3m) (FY, 2025)	Net income $14b (FY, 2025)	Net income ($2.8b) (FY, 2025)	Net income $4.5b (FY, 2025)	Net income N/A
Operating ⚠
Patents (US)	Patents (US) N/A	Patents (US) N/A	Patents (US) 170 (FY, 2021)	Patents (US) 31 (FY, 2020)	Patents (US) N/A
Funding
Total funding raised	Total funding raised $ 16.9m	Total funding raised $ 6.5m	Total funding raised $ 1.8b	Total funding raised $ 53.9m	Total funding raised $ 3.5m